These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 27976927)

  • 21. Management ... the working day of a health services manager. Guy's & St Thomas' Hospital Trust.
    Matthews T
    Health Serv Manage; 1993 Jun; 89(6):34-5. PubMed ID: 10126782
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [PCSK9 inhibition as the new hope for patients with familial hypercholesterolemia, statin intolerance and eventually for those at the highest cardiovascular risk? Focused on alirocumab, Praluent®].
    Češka R
    Vnitr Lek; 2015 Nov; 61(11):946-51. PubMed ID: 26652782
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advances in cardiac lead extraction. Interview by Caroline Telfer.
    Zaidi A
    Future Cardiol; 2013 Nov; 9(6):775-7. PubMed ID: 24180535
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PCSK9 inhibitors: monoclonal antibodies for the treatment of hypercholesterolemia.
    Paton DM
    Drugs Today (Barc); 2016 Mar; 52(3):183-92. PubMed ID: 27186592
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy.
    Jetty V; Glueck CJ; Lee K; Goldenberg N; Prince M; Kumar A; Goldenberg M; Anand I; Wang P
    Vasc Health Risk Manag; 2017; 13():247-253. PubMed ID: 28740397
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alirocumab for hyperlipidemia: ODYSSEY Phase III clinical trial results and US FDA approval indications.
    Roth EM
    Future Cardiol; 2016 Mar; 12(2):115-28. PubMed ID: 26785741
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alirocumab: First Global Approval.
    Markham A
    Drugs; 2015 Sep; 75(14):1699-705. PubMed ID: 26370210
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PCSK9 inhibitors: a non-statin cholesterol-lowering treatment option.
    Pokrywka GS
    Postgrad Med; 2018 Apr; 130(3):287-298. PubMed ID: 29411675
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interview: Investigating immunomodulators among the Actinomycetales. Interview by Hannah Wilson.
    Stanford JL
    Immunotherapy; 2013 May; 5(5):449-52. PubMed ID: 23638740
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: evolocumab.
    Dahagam C; Goud A; Abdelqader A; Hendrani A; Feinstein MJ; Qamar A; Joshi PH; Swiger KJ; Byrne K; Quispe R; Jones SR; Blumenthal RS; Martin SS
    Future Cardiol; 2016 Mar; 12(2):139-48. PubMed ID: 26911578
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.
    Robinson JG; Farnier M; Krempf M; Bergeron J; Luc G; Averna M; Stroes ES; Langslet G; Raal FJ; El Shahawy M; Koren MJ; Lepor NE; Lorenzato C; Pordy R; Chaudhari U; Kastelein JJ;
    N Engl J Med; 2015 Apr; 372(16):1489-99. PubMed ID: 25773378
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Promising new developments in cervical cancer.
    McCormack M; Lake F
    Future Oncol; 2014; 10(9):1541-4. PubMed ID: 25145424
    [TBL] [Abstract][Full Text] [Related]  

  • 33. My Ward: The Story of St Thomas', Guy's and the Evelina Children's Hospitals and their Ward Names Wendy Mathews My Ward: The Story of St Thomas', Guy's and the Evelina Children's Hospitals and their Ward Names | Walpole House Publishing £5 I 135pp | 9780956394200 0956394205 [Formula: see text].
    Nurs Manag (Harrow); 2011 May; 18(2):11. PubMed ID: 27351248
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New multipoint pacing technology for heart failure patients. Interview by Caroline Telfer.
    Betts T
    Future Cardiol; 2013 Nov; 9(6):771-3. PubMed ID: 24180534
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alirocumab for the treatment of hyperlipidemia in high-risk patients: an updated review.
    Farnier M
    Expert Rev Cardiovasc Ther; 2017 Dec; 15(12):923-932. PubMed ID: 29171769
    [TBL] [Abstract][Full Text] [Related]  

  • 36. What is it like to work for a pharmaceutical company? Interview by Barbara J. Linney.
    Kaufman EA
    Physician Exec; 2001; 27(2):80-3. PubMed ID: 11291228
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM-INSULIN trial.
    Cariou B; Leiter LA; Müller-Wieland D; Bigot G; Colhoun HM; Del Prato S; Henry RR; Tinahones FJ; Letierce A; Aurand L; Maroni J; Ray KK; Bujas-Bobanovic M
    Diabetes Metab; 2017 Oct; 43(5):453-459. PubMed ID: 28347654
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heart failure gene therapy: closer to reality. Professor Walter Koch speaks to Christine Forder, commissioning editor.
    Koch WJ
    Future Cardiol; 2009 Mar; 5(2):117-9. PubMed ID: 19371185
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Navigating the clinical trial pathway: Conception, design, execution, and results dissemination.
    Sampalis JS; Watson J; Boukas S; Boukas M; Harvey N; Machado S; Bordeleau M; Rampakakis E
    Surgery; 2017 Mar; 161(3):576-583. PubMed ID: 28190508
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interview with Justin Davies and Andrew Tochterman.
    Davies J; Tochterman A
    Future Cardiol; 2017 Jul; 13(4):323-326. PubMed ID: 28660783
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.